Multidisciplinary management of a patient with synchronous neoplasms: A case report of breast cancer plus pheochromocytoma
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sheila Maria Huertas Tirado, Jose Luis Vargas Mejia, Ciro Espejo Alencastre

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
DOI:
https://doi.org/10.33821/824Keywords:
Synchronous neoplasms, pheochromocytoma, breast cancer, clinical caseAbstract
Introduction: Synchronous neoplasms are a rare phenomenon. It is reported that patients with breast cancer and synchronous neoplasms most frequently develop malignant tumors in the thyroid gland (71%) or the gynecological tract (9.7%). There is no established association with pheochromocytoma, as the presence of both synchronous neoplasms is extremely rare. This case describes an atypical association of two neoplasms and their multidisciplinary approach in a public institution in Peru. Case report: Postmenopausal patient who presented with a breast tumor compatible with malignant neoplasm. Extension studies incidentally evidenced an adrenal mass with characteristics of malignancy, initially suspecting a focus of secondary metastasis. Complementary studies evidenced elevated serum and urinary metanephrines, leading to the diagnosis of pheochromocytoma. Initially, a right adrenalectomy was performed, followed later by a radical mastectomy, obtaining high-risk pathology (grade II with lymphovascular invasion, perineural invasion, and nodal macrometastases). Discussion: Synchronous neoplasms present a challenge in the diagnosis and treatment of the oncological patient. In this case, the surgical management of pheochromocytoma was prioritized due to the risk of cardiovascular complications. Delay in the management of breast pathology is a factor associated with the presence of high-risk scenarios, characterized by disease in more advanced stages, a greater probability of tumor progression, and worst oncological outcomes. Conclusions: The management of multiple neoplasms should be individualized according to the characteristics of each neoplasm and risk of complications. It is necessary to report cases of atypical associations of multiple neoplasms to broaden the diagnostic spectrum and improve the therapeutic approach for patients.
Downloads
References
De Luca A, Frusone F, Vergine M, Cocchiara R, La Torre G, Ballesio L, et al. Breast Cancer and Multiple Primary Malignant Tumors: Case Report and Review of the Literature. In Vivo. 2019;33(4):1313-24. https://doi.org/10.21873/invivo.11605
Pan SY, Huang CP, Chen WC. Synchronous/Metachronous Multiple Primary Malignancies: Review of Associated Risk Factors. Diagnostics (Basel). 2022;12(8):1940. https://doi.org/10.3390/diagnostics12081940
Lv M, Zhang X, Shen Y, Wang F, Yang J, Wang B, et al. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors. Medicine. 2017;96(17):e6799. https://doi.org/10.1097/MD.0000000000006799
Pariyada Tanjak, Bhoom Suktitipat, Nutchavadee Vorasan, Panudeth Juengwiwattanakitti, Benjarat Thiengtrong, Cholticha Songjang, et al. Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study. 2021;21:1007. https://doi.org/10.1186/s12885-021-08766-9
Kwon JH, Kim H, Lee JK, Hong YJ, Kang HJ, Jang YJ. Incidence and Characteristics of Multiple Primary Cancers: A 20-Year Retrospective Study of a Single Cancer Center in Korea. Cancers (Basel). 2024;16(13):2346. https://doi.org/10.3390/cancers16132346
Singnurkar A, Swaminath A, Metser U, Langer DL, Darling GE, Pond GR. The impact of synchronous malignancies on survival in patients with early stage curable non-small-cell lung cancer. Cancer Treat Res Commun. 2020;25:100246. https://doi.org/10.3390/10.1016/j.ctarc.2020.100246
Shin S, Park H, Sung Y, Yoo C, Dae Wook Hwang, Park J, et al. Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. Cancer Research and Treatment. 2018;50(4):1175-85. https://doi.org/10.4143/crt.2017.494
Amer M. Multiple neoplasms, single primaries, and patient survival. Cancer Management and Research. 2014;6:119-26. https://doi.org/10.2147/CMAR.S57378
Chen H, Yin S, Xiong Z, Li X, Zhang F, Chen X, et al. Clinicopathologic characteristics and prognosis of synchronous colorectal cancer: a retrospective study. BMC Gastroenterology. 2022;22(1):108. https://doi.org/10.1186/s12876-022-02153-9
Hao L, Zhang L, Xu C, Jiang M, Zhu G, Guo J. Multiple synchronous primary malignant neoplasms: A case report and literature review. Oncology Letters. 2023;26(4):428. https://doi.org/10.3892/ol.2023.14014
Lu M, Zhang X, Chu Q, Chen Y, Zhang P. Susceptibility genes associated with multiple primary cancers. Cancers. 2023;15(24):5788. https://doi.org/10.3390/cancers15245788/
Sas-Korczy?ska B, Mitu? JW, Kamzol W, Ko?odziej Rzepa M, Jakubowicz J, Wysocki WM. Synchronous malignancies in patients with breast cancer. Nowotwory J Oncol. 2018;67(6):336-41. https://doi.org/10.5603/NJO.2017.0055
Oprita A, Cotan H, Nitipir C. The prognostic implications of synchronous cancers in breast cancer patients. Cureus. 2025 (septiembre 08 corrección);17(9):c285. https://doi.org/10.7759/cureus.c285
Dahake N, Tushir A, Padmanabhan A. Synchronous breast cancer and pheochromocytoma: a case series [abstract]. Cancer Res. 2024;84(9 Suppl):PO5-20-11. https://doi.org/10.1158/1538-7445.SABCS23-PO5-20-11
Cruz AS, Sa RP, Torres R, Abreu JP. Individualized anesthetic management of a patient with pheochromocytoma and concurrent breast cancer: A case report. Cureus. 2024;16(5):e59751. https://doi.org/10.7759/cureus.59751
Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77-90. https://doi.org/10.1016/S1470-2045(22)00694-5
Rastogi P, O’Shaughnessy J, Martín M, Boyle FM, Cortés J, Rugo HS, et al. adjuvant abemaciclib plus endocrine therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42(9):987-93. https://doi.org/10.1200/JCO.23.01994
Slamon D, Oleg Lipatov, Zbigniew Nowecki, McAndrew N, Bozena Kukielka-Budny, Daniil Stroyakovskiy, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390(12):1080-91. https://doi.org/10.1056/NEJMoa2305488
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: Final invasive disease-free survival results from the NATALEE trial. Ann Oncol. 2024;35(12):1070-81. https://doi.org/10.1016/j.annonc.2024.10.015/
Brewczy?ski A, Kolasi?ska-?wik?a A, Jab?o?ska B, Wyrwicz L. Pheochromocytomas and paragangliomas— current management. Cancers (Basel). 2025;17(6):1029. https://doi.org/10.3390/cancers17061029
Ilanchezhian M, Jha A, Pacak K, Del Rivero J. Emerging treatments for advanced/metastatic pheochromocytoma and paraganglioma. Curr Treat Options Oncol. 2020;21(11):85. https://doi.org/10.1007/s11864-020-00787-z
Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, et al. Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab. 2009;94(8):2850-6. https://doi.org/10.1210/jc.2008-2697
Batra H, Jason Aboudi Mouabbi, Ding Q, Sahin AA, Maria Gabriela Raso. Lobular Carcinoma of the Breast: A comprehensive review with translational insights. Cancers (Basel). 2023;15(22):5491. https://doi.org/10.3390/cancers15225491
Panagiotis K, Zotou M, Antonopoulou V, Geordiadi S, Kyriakou A, et al. A rare case of silent metastatic pheochromocytoma with a breast metastasis. Endocrine Abstr. 2025;110:EP121. https://doi.org/10.1530/endoabs.110.EP121
Liu XJ, Shen P, Wang XF, Sun K, Sun FF. Solitary adrenal metastasis from invasive ductal breast cancer: An uncommon finding. World J Surg Oncol. 2010;8:7. https://doi.org/10.1186/1477-7819-8-7
